AD-201(AD-201) - 在研适应症：高脂血症，高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

incrementally modified drug(Addpharma)

靶点-

作用机制-

治疗领域

心血管疾病内分泌与代谢疾病

在研适应症

高脂血症高血压

非在研适应症-

原研机构

Addpharma, Inc.

在研机构

Addpharma, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2021-07-12),

高脂血症高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 AD-201 相关的临床试验

KCT0009387 / Completed临床1期

An open-label, randomized, 2-sequence, 4-period, sinlge-dose, repeated-crossover study to evaluate the pharmacokinetics and the safety of AD-201 compared to coadministration of AD-2011 with AD-2012 in healthy adult volunteers

开始日期2019-10-12

申办/合作机构

Addpharma, Inc.

100 项与 AD-201 相关的临床结果

登录后查看更多信息

100 项与 AD-201 相关的转化医学

登录后查看更多信息

100 项与 AD-201 相关的专利（医药）

登录后查看更多信息

1

项与 AD-201 相关的文献（医药）

Bioengineering

Identification of a Novel Wnt Antagonist Based Therapeutic and Diagnostic Target for Alzheimer’s Disease Using a Stem Cell-Derived Model

Article

作者: Gamit, Naisarg ; Dharmarajan, Arun ; Patil, Manasi ; Sethi, Gautam ; Warrier, Sudha

Currently, all the existing treatments for Alzheimer’s disease (AD) fail to stall progression due to longer duration of time between onset of the symptoms and diagnosis of the disease, raising the necessity of effective diagnostics and novel treatment. Specific molecular regulation of the onset and progression of disease is not yet elucidated. This warranted investigation of the role of Wnt signaling regulators which are thought to be involved in neurogenesis. The AD model was established using amyloid beta (Aβ) in human mesenchymal stem cells derived from amniotic membranes which were differentiated into neuronal cell types. In vivo studies were carried out with Aβ or a Wnt antagonist, AD201, belonging to the sFRP family. We further created an AD201-knockdown in vitro model to determine the role of Wnt antagonism. BACE1 upregulation, ChAT and α7nAChR downregulation with synapse and functionality loss with increases in ROS confirmed the neurodegeneration. Reduced β-catenin and increased AD201 expression indicated Wnt/canonical pathway inhibition. Similar results were exhibited in the in vivo study along with AD-associated behavioural and molecular changes. AD201-knockdown rescued neurons from Aβ-induced toxicity. We demonstrated for the first time a role of AD201 in Alzheimer’s disease manifestation, which indicates a promising disease target and biomarker.

100 项与 AD-201 相关的药物交易

登录后查看更多信息